Study to test solanezumab's potential in preventing Alzheimer's

01/20/2013 | Washington Times, The

Dr. Reisa Sperling, director of the Alzheimer's disease center at Brigham and Women's Hospital in Boston, will be heading a study that will test an experimental drug from Eli Lilly & Co. called solanezumab. The study, to include 1,000 people with plaque buildup but no signs of dementia, will test whether the drug can prevent the development of Alzheimer's when administered before symptoms manifest. Researchers are also paying close attention to whether the drug can at least hinder the speed of cognitive degeneration.

View Full Article in:

Washington Times, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA